REG - Ergomed plc - Board Appointment

ErgomedAnnouncement

18/06/2019 15:05

RNS Number : 6575C
Ergomed plc
18 June 2019
 


Board appointment
Appointment of Richard Barfield as an Executive Director to the Board of Ergomed plc
Guildford, UK - 18 June 2019: further to the Company's announcement on 4 June 2019, Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company") today announces that Richard Barfield, its Chief Financial Officer, is appointed to the board as an Executive Director with immediate effect. Stuart Jackson, former Chief Financial Officer of the Company, has resigned from the Board of the Company with immediate effect but will continue to be employed by the Company until early July.
Since qualifying as a chartered accountant, Richard has more than 25 years' experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of a world-leading teaching hospital. 
Richard has proven experience within the contract research sector having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m. The eventual sale of Chiltern to Covance, a division of the US-listed healthcare company Laboratory Corporation of America Holdings (LabCorp), in late 2017 for $1.2bn delivered a cash return of over 4x to investors in Chiltern's December 2013 refinancing.
Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Richard Barfield's appointment.
Mr Richard Timothy Barfield, aged 61, currently holds and has held the following directorships in the past five years:




Current directorships:


RDB NOTO




Directorships in the past five years:


Chiltern Clinical Research (Philippines) Inc.
Chiltern Clinical Research KK
Chiltern Clinical Research S.R.L.
Chiltern Clinical Research YH
Chiltern International (Canada) Ltd.
Chiltern International (Hong Kong) Ltd.
Chiltern International AB
Chiltern International B.V.
Chiltern International BVBA/Sprl
Chiltern International EOOD
Chiltern International GmbH
CHILTERN INTERNATIONAL GROUP LIMITED
CHILTERN INTERNATIONAL HOLDINGS LIMITED
Chiltern International Inc.
Chiltern International Kft
CHILTERN INTERNATIONAL LIMITED(1)
Chiltern International Ltd.(2)
Chiltern International Portugal Lda
Chiltern International Pte Ltd
Chiltern International Pty. Ltd.
Chiltern International Pvt. Ltd.
Chiltern International SARL
Chiltern International SP Zoo
Chiltern International Spain SA
Chiltern International SRL(3)
Chiltern International SRL(4)
Chiltern International sro
Chiltern International Switzerland SARL
Chiltern International Taiwan Ltd.
Chiltern Klinik Arastirma Organizayson Limited Sirketi
Chiltern Pharmaceutical and Technology Consulting (Shanghai) Co. Ltd.
Chiltern Research International (Singapore) Ltd.
Chiltern Research International Pty. Ltd.
Covance Clinical Development GmbH
ENDPOINT CLINICAL (UK) LTD
Endpoint Clinical India Private Limited
Endpoint Clinical, Inc.
HAVENFERN LIMITED
Integrated Development Associates Co., Ltd.
OCKHAM DEVELOPMENT GROUP (HOLDINGS) UK LIMITED
Ockham Development Group Inc.
OCKHAM EUROPE LIMITED
Ockham India Clinical Research and Data Services Pvt. Ltd.
Ockham Oncology AB
Ockham Oncology GmbH 
Ockham Oncology Kft
Ockham Oncology Pty. Ltd.
Ockham Oncology S.L.U.
Ockham Oncology SPRL (Belgium)
Pacific Clinical Research India Limited
TCR International B.V.
TCR Latin America B.V.
Theorem Clinical Research Holdings B.V.
Theorem Clinical Research Holdings Inc.
Theorem Clinical Research Inc.
Theorem Clinical Research Kft
THEOREM CLINICAL RESEARCH LIMITED
Theorem Clinical Research Pte. Ltd.(5)
Theorem Clinical Research Pte. Ltd.(6)
Theorem Clinical Research Pty Ltd
Theorem Clinical Research SARL
Theorem Clinical Research SRL
Theorem Clinical Research sro
Theorem CR Inc.
Theorem Foreign Representation Company
Theorem Research Associates, Inc.




Notes on duplicate directorship disclosures:
(1)  Note: entity registered in the UK.
 
(2) Note: entity registered in Israel.
(3) Note: entity registered in Argentina.
(4) Note: entity registered in Italy.
(5) Note: entity registered in Singapore.
(6) Note: Philippines branch office of entity registered in Singapore.
Mr Barfield holds 100,000 ordinary shares of 1p each in the Company, representing 0.21% of the Company's issued share capital.
Enquiries:




Ergomed plc


Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)


 




 


 




Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)


 
 




 




 


 




 


 




Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Matthew Neal / Olivia Manser


ergomed@Consilium-comms.com




 


 




MC Services - for Continental European enquiries
Anne Hennecke


Tel: +49 211 5292 5222




 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEALKPFEFNEFF